The share price of Relief Therapeutics Holding AG (RLFTF) closed the previous session at $0.4240 after rising 14.66%. A recent volume of 46.80M shares was higher than its 14M average daily volume. Further, shares of the company have traded in a price range of $0.3380 to $0.4999.
Relief Therapeutics Holding AG (RLFTF) focuses on molecules of natural origin (peptides and proteins) that have been clinically tested and used in human patients for significant periods or demonstrate a strong scientific rationale. Currently, Relief is focusing on developing new treatments for respiratory diseases. In two late-stage U.S. clinical trials for the respiratory deficiency caused by COVID-19, RLF-100 (aviptadil) is being investigated as a non-drug modulator. The company holds a patent for RLF-100 in various foreign countries and the United States.
HOW DID THAT HAPPEN
February 24, 2021, Relief Therapeutics Holding AG (RLFTF) announced that NeuroRx, Inc. released Phase 2b/3 data from RLF-100(TM) trial treat Respiratory Failure in Critical COVID-19 patients.
NeuroRx, Inc. REVEALED that the Phase 2b/3 trial of ZYESAMI FOR the treatment of Respiratory Failure in critically ill patients with Covid-19. They were treated with high flow nasal oxygen, which has demonstrated robust improvement in Recovery’s primary endpoint from Respiratory Failure, with discharge from the hospital and intensive care unit by day 28.
At the start of the clinical trial, High Flow Nasal Oxygen was not expected to be the primary treatment approach for Covid-19 patients. Mechanical ventilation was reserved only for those whose blood oxygen levels could not be maintained with this less invasive approach. In collaboration with NeuroRx and RELIEF THERAPEUTICS Holdings AG (SIX: RLF; OTCQB: RLFTF), the trial was conducted at ten U.S. hospitals. A business combination agreement was signed between NeuroRx and Big Rock Partners Acquisition Corporation (NASDAQ: BRPA).
Many experts consider that biotechnology is entering a golden age. Previously unimaginable ways to treat and prevent diseases are now available thanks to a new medical science era. The biotech sector offers an excellent opportunity for investors during this period. However, investors usually know it’s a slow-growing market in the biotech market since companies rely on FDA approvals and feedback.